faCellitate GmbH has appointed Dr. Christoph Petry, as Managing Director and CEO. Dr. Petry spun-out Sividon Diagnostics from Siemens Healthcare in 2010. Serving as Sividon’s CEO he oversaw the development of EndoPredict, a new standard to target breast cancer therapy and later successfully sold the company to Myriad Genetics. As a Managing Director he then joined m2p-labs, a company focusing on microbioreactor technology. After having restructured the company, he managed m2p-labs’ sale to Danaher corporation and headed the former-m2p-labs’ Engineering and Operations Departments throughout the company’s integration with Danaher.  In October 2022 Dr. Petry accepted the assignment to become faCellitate’s new CEO. He will manage the company jointly with Dr. Simon Widmaier, founder and COO of faCellitate. “We are very pleased to welcome Dr. Petry on board.”, says Dr. Klaus Schollmeier, Chairman of faCellitate’s Board. “He is contributing almost three decades of experience in the life science industry into our company – including a remarkable track record of two successful company exits in the venture capital area.” “faCellitate’s technology is well developed”, Dr. Christoph Petry is convinced: “The BIOFLOAT™ product line has demonstrated an impressive growth powered by excellent performance. It will serve as the basis for additional high-value products already under development that will help to propel faCellitate’s future growth.”